María Elena A. D.
- Country
- Spain
- Department
- Hematología
Research Overview
- Phase III Trial Comparing Extended Lenalidomide-Bortezomib-Dexamethasone with Early Rescue vs. Isatuximab-Lenalidomide-Bortezomib-Dexamethasone vs. Isatuximab-Lenalidomide-Iberdomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Candidates for Autologous Stem Cell Transplantation
- Evaluation of Brentuximab Vedotin-ESHAP Versus ESHAP in Relapsed/Refractory Classical Hodgkin Lymphoma: A Phase IIb Randomized Study
Data & Insights
Has run more than one trial at 17 of 57 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating and researching classical Hodgkin's lymphoma, with particular focus on developing therapeutic strategies for patients with relapsed and refractory disease conditions.
- Lymphoma Treatment Innovations
- Salvage Therapy Approaches
- Response Assessment Methods
Their research explores novel therapeutic combinations incorporating targeted therapies for lymphoma management.
Multiple Myeloma
The investigator focuses on advancing treatment protocols for newly diagnosed multiple myeloma, investigating innovative combination therapies and treatment sequences.
- Novel Drug Combinations
- Treatment Optimization
- Response Monitoring
Their work includes evaluation of targeted therapies and immunotherapy approaches in multiple myeloma treatment.
Therapeutic Innovation
The investigator develops advanced treatment strategies incorporating stem cell therapy and novel therapeutic agents in hematologic malignancies.
- Treatment Sequencing
- Therapy Optimization
- Clinical Outcomes Assessment
Their research encompasses evaluation of targeted therapies and immunological approaches in blood cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.